Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of cyclosporine in the treatment of COVID-19 pneumonia
2020-002123-11Phase 4Active
- Sponsor
- Tatiana Cobo Ibáñez
- Start
- May 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of cyclosporine in coronavirus pneumonia (2 arms), sponsored by Tatiana Cobo Ibáñez. Primary endpoints: Complete response rate at 3 months and Lack of response characterization at 3 months. Started May 2020; status: active.
02
Drugs
cyclosporine
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-002123-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002123-11.